Evidence map›Paper›PMID 30318718›Full record

ArticleHIV medicine2019

Identification and characterization of HIV positive Ethiopian elite controllers in both Africa and Israel.

Y K Kiros, H Elinav, A Gebreyesus, H Gebremeskel, J Azar, D Chemtob, H Abreha, D Elbirt, E Shahar, M Chowers and 6 more

Open access · bronzeAbstract read
In one paragraph

Article in HIV medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 9 institutions in 4 countries.

Y K KirosMekelle University College of Health Sciences, Mekelle, Tigray, Ethiopia.
H ElinavClinical Microbiology and Infectious Diseases Department, Hadassah University Medical Center, Jerusalem, Israel.ORCID 0000-0001-9046-8130
A GebreyesusMekelle University College of Health Sciences, Mekelle, Tigray, Ethiopia.
H GebremeskelMekelle University College of Health Sciences, Mekelle, Tigray, Ethiopia.
J AzarInternal Medicine Division, Hadassah University Medical Center, Jerusalem, Israel.
D ChemtobDepartment of Tuberculosis and AIDS, Ministry of Health, Jerusalem, Israel.ORCID 0000-0002-2864-9982
H AbrehaMekelle University College of Health Sciences, Mekelle, Tigray, Ethiopia.
D ElbirtThe Allergy, Clinical Immunology and AIDS Unit, Kaplan Medical Center, Rehovot, Israel.
E ShaharInstitute of Allergy, Immunology and AIDS Rambam Medical Center, Haifa, Israel.
M ChowersInfectious Diseases Unit, Meir Medical Center, Kfar Saba, Israel.
D TurnerCrusaid Kobler AIDS Center, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Z GrossmanClinical Microbiology and Infectious Diseases Department, Hadassah University Medical Center, Jerusalem, Israel.
A HaileMekelle University College of Health Sciences, Mekelle, Tigray, Ethiopia.
R E SuttonDivision of Infectious Diseases, Department of Medicine, Yale University School of Medicine, New Haven, CT, USA.
S L MaayanDivision of Infectious Diseases, Barzilai Medical Center, Ashkelon, Israel.
D WoldayMekelle University College of Health Sciences, Mekelle, Tigray, Ethiopia.
University of Bahrain · BHHadassah Medical Center · ILBarzilai Medical Center · ILIsrael Ministry of Health · ILKaplan Medical Center · ILMeir Medical Center · ILRambam Health Care Campus · ILTel Aviv Sourasky Medical Center · ILYale University · US

Funding

Host Genetic Control of HIVDP1DA036463 · NIDA · YALE UNIVERSITY · PI SUTTON, RICHARD · 2013 to 2017
$3.7M
Mechanisms of transcriptional regulation of ccr5 and host genetic control of HIVR01AI150334 · NIAID · YALE UNIVERSITY · PI SUTTON, RICHARD · 2020 to 2024
$3.5M
NIAID NIH HHS R01 AI150334NIDA NIH HHS DP1 DA036463
6 · The paper itself

Abstract

objectivesHIV elite controllers (ECs) are a unique subgroup of HIV-positive patients who are long-term virologically suppressed in the absence of antiretroviral treatment (ART). The prevalence of this subgroup is estimated to be < 1%. Various cohorts of ECs have been described in developed countries, most of which have been demographically heterogeneous. The aim of this study was to identify ECs in two large African cohorts and to estimate their prevalence in a relatively genetically homogenous population.

methodsWe screened two cohorts of HIV-positive Ethiopian patients. The first cohort resided in Mekelle, Ethiopia. The second was comprised of HIV-positive Ethiopian immigrants in Israel. In the Mekelle cohort, ART-naïve subjects with stable CD4 counts were prospectively screened using two measurements of viral load 6 months apart. Subjects were defined as ECs when both measurements were undetectable. In the Israeli cohort, subjects with consistently undetectable viral loads (mean of 17 viral load measurements/patient) and stable CD4 count > 500 cells/μL were defined as ECs.

resultsIn the Mekelle cohort, 16 of 9515 patients (0.16%) fitted the definition of EC, whereas seven of 1160 (0.6%) in the Israeli cohort were identified as ECs (P = 0.011).

conclusionsThis is the first large-scale screening for HIV-positive ECs to be performed in entirely African cohorts. The overall prevalence of ECs is within the range of that previously described in developing countries. The significant difference in prevalence between the two cohorts of similar genetic background is probably a consequence of selection bias but warrants further investigation into possible environmental factors which may underlie the EC state.

Indexed as

AdultCD4 Lymphocyte CountCohort StudiesEmigrants and ImmigrantsEthiopiaFemaleHIV-1HIV InfectionsHumansIsraelMaleMass ScreeningPrevalenceViral LoadYoung Adultelite controllersEthiopiaHIVIsrael

Identifiers

PMID30318718
PMCPMC6510948
OpenAlexW2897066685

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.